BIOCON INDIA LIMITED.

ABOUT BIOCON

"Our ability to continuously scale new heights across the

biopharmaceutical value chain enables us to realise the
promise of future therapeutics." -Kiran Mazumdar-Shaw,
Chairman & Managing Director

Biocon is a fully integrated healthcare company that

delivers innovative biopharmaceutical solutions. From
discovery to development and commercialisation, we have
the defining science, cost-effective drug development
capabilities and significant manufacturing capacity to move
ideas to market.

Leveraging India’s globally competitive cost base and

exceptional scientific people resource, we are advancing our
in-house R&D programs, while also providing custom and
clinical research services to international pharmaceutical and
biotechnology majors through our subsidiary companies,
Syngene and Clinigene.

Biocon has rapidly developed a robust drug pipeline, led

by monoclonal antibodies and several other molecules at
exciting stages in the biopharmaceutical value chain. With
the successful commercial launch of our first anti-cancer
drug and several promising discovery partnerships in the
clinic, we remain committed to scaling new heights in
frontier science and achieving new milestones in affordable
medicine.

BOARD OF DIRECTORS:

Dr. Neville Bain

- Chairman, Institute of Directors, UK
- Board Member, Scottish & Newcastle
Plc., Provexis Ltd.
- Former Group CEO, Coats Viyella Plc.
- Former Deputy Group Chief Executive
and Finance Director, Cadbury
Schweppes Plc.
- Author of several management books
on corporate governance, strategy
and people management

Prof. Charles L. Cooney

- Professor, Chemical & Biochemical
Engineering, MIT, USA
- Director, Genzyme Inc. and
Bio-Processors Inc.
- Recipient of prestigious awards,
including Gold Medal of the Institute
of Biotechnology Studies and
Distinguished Service Award
from the American Chemical Society

Dr. Bala S. Manian

 - Chairman and Founder, Reametrix Inc.
- Co-founder, Quantum Dot Corporation
and Surromed Corporation, USA
- Expert in the design of electro-optical
systems
- Authored several peer-reviewed
scientific publications and holder of
many patents
- Recognised through numerous
awards for contributions as educator,
inventor and entrepreneur, including
Technical Academy Award in Digital
Cinematography by Academy of
Motion Pictures, Arts and Sciences

Mr. Suresh Talwar

- Partner, Talwar Thakore & Associates
- Director, Cadbury India Ltd., Birla
Sun Life Insurance Co. Ltd., L&T Ltd.
- Area of professional specialisation
includes corporate law and related fields
- Legal counsel to numerous Indian
companies, multinational corporations
and Indian/foreign banks

Ms. Kiran Mazumdar-Shaw

- Chairman & Managing Director, Biocon
- First generation entrepreneur with
more than 32 years experience
in biotechnology and industrial enzymes
- Master Brewer, Ballarat University,
Australia
- Awarded the Padmabhushan, one of
India’s highest civilian awards for
her pioneering efforts in
Biotechnology, 2005
 Mr. John Shaw
- Vice Chairman, Biocon
- Served in senior corporate positions
at various locations around the world
- Chairman, Madura Coats Ltd.
between 1991-1998

Prof. Ravi Mazumdar

- University Research Chair Professor,
Department of Electrical and
Computer Engineering, University
of Waterloo, Canada
- Fellow of the Institute of Electrical
and Electronics Engineers (IEEE) and
Fellow of the Royal Statistical Society

ABOUT KEY FACTS AREA OF BIOCON:

Biocon Limited It is a fully integrated biopharmaceutical

company focused on biopharmaceuticals, custom research
and clinical research.

SUBSIDIARY COMPANIES:

Syngene International Limited is a custom research organisation

offering synthetic chemistry and molecular biology services for early
stage drug discovery and development.

Clinigene International Limited is a clinical research organisation

offering Phase I-IV clinical trials and studies for novel/generic
molecules to international pharmaceutical majors.
Biocon Biopharmaceuticals Private Limited (BBPL) began as a
joint venture with CIMAB to develop and market a range of
monoclonal antibodies and cancer vaccines. In March 2010, Biocon
acquired CIMAB’s 49% stake and BBPL became a 100% subsidiary.

AxiCorp GmbH is a Friedrichsdorf (Germany) based

pharmaceutical marketing company and is amongst the fastest
growing in Europe. Biocon Limited acquired a majority stake in
AxiCorp GmbH (78%) in February, 2008.

NeoBiocon FZ LLC is a research and marketing pharmaceutical

company based in Abu Dhabi. Incorporated in January 2008,
NeoBiocon is a 50:50 joint venture with Dr. B.R.Shetty, Managing
Director of NeoPharma, Abu Dhabi.

INVESTORS:
"We are committed to delivering value to all our stakeholders. By
leveraging our proprietary products and technologies we will achieve
robust growth and sustained financial performance."

- Murali Krishnan K.N, President, Finance

Welcome to Biocon's Investor Relations. Here, we feature

comprehensive information on all aspects of the Company that
concern and interest the investor. From access to financial data,
stock quotes, FAQs and more, we give our existing and potential
investors all relevant data and updates on corporate governance and
the overall progress of the company.

THE STOCK OVERVIEW:

NSE
dhgt251654144fLayoutI Code : View Chart
nCell1fHidden0fPseudoI BIOCON
nline0fLayoutInCell1
Currency : Rupees

dhgt251655168fLayoutI
nCell1fHidden0fPseu
doInline0fLayoutInCell1

Price

371 Day High 387

Bid 370.6 Day Low 369.25

dhgt251656192fLayoutInCell1fHidden0fPseudoInline0fLayoutInCell1

dhgt251657216fLayoutI
nCell1fHidden0fPseu
doInline0fLayoutInCell1

Offer

371.3 52 Week High 472.55

dhgt251658240fLayoutI -11.85 52 Week Low 250.1

nCell1fHidden0fPseudoI
nline0fLayoutInCell1

Change On Day
dhgt251659264fLayoutI
nCell1fHidden0fPseudoI
nline0fLayoutInCell1
dhgt251660288fLayoutI
nCell1fHidden0fPseu
doInline0fLayoutInCell1

Percentage Change

-3.10% Opening Price 380.2

dhgt251661312fLayoutI
nCell1fHidden0fPseudoI
nline0fLayoutInCell1

Last Trade Date

10:24AM
26-11-2010 Last Trade Time

Daily Volume 215,249 Prev. Closing 382.85

THE FILE CHART:

THE CLOSING STOCK PRICE ( 30 Nos.)
 CLOSE
SYMBOL SERIES DATE PRICE
BIOCON EQ 30-Aug-10 343.6
339.9
BIOCON EQ 31-Aug-10
341.2
BIOCON EQ 1-Sep-10
343.45
BIOCON EQ 2-Sep-10
345.75
BIOCON EQ 3-Sep-10
344.55
BIOCON EQ 6-Sep-10
348.05
BIOCON EQ 7-Sep-10
347.3
BIOCON EQ 8-Sep-10
345.85
BIOCON EQ 9-Sep-10
343.75
BIOCON EQ 13-Sep-10
341.7
BIOCON EQ 14-Sep-10
342.8
BIOCON EQ 15-Sep-10
341.4
BIOCON EQ 16-Sep-10
353.8
BIOCON EQ 17-Sep-10
354.85
BIOCON EQ 20-Sep-10
351.4
BIOCON EQ 21-Sep-10
351
BIOCON EQ 22-Sep-10
350.8
BIOCON EQ 23-Sep-10
351.8
BIOCON EQ 24-Sep-10
356.2
BIOCON EQ 27-Sep-10
367.7
BIOCON EQ 28-Sep-10
361.8
BIOCON EQ 29-Sep-10
359.3
BIOCON EQ 30-Sep-10
366.25
BIOCON EQ 1-Oct-10
386.7
BIOCON EQ 4-Oct-10
381.5
BIOCON EQ 5-Oct-10
379.75
BIOCON EQ 6-Oct-10
401.65
BIOCON EQ 7-Oct-10
410.95
BIOCON EQ 8-Oct-10
402.85
BIOCON EQ 11-Oct-10
398.95
BIOCON EQ 12-Oct-10
THE RUN TEST:
 IN THE WEAK FORM OF MARKET RUN TEST IS DONE TO KNOW THE
CURRENT MATKET FLUCTIONS SO THAT INVESTORS WOULD KNOW
WHETHER THE MARKET IS EFFICIENT OR NOT.

THE RUN TEST WAS ALSO DONE BY FAMA TO FIND OUT IF PRICE
CHANGES WERE LIKELY TO BE FOLLOWED BY FURTHER PRICE
CHANGES OF THE SAME SIGN. HE MADE THE RUN TEST BECAUSE
CORRELATION COEFFICIENTS WERE TOO OFTEN DOMINATED BY
EXTREME VALUES AND THEY INFLUNCE THE RESULTS OF
CALCULATION TO DETERMINE THE CORRELATION COEFFICIENT.